vTv Therapeutics Inc.
North Carolina, United States · Biopharma, Biotechnology, Healthcare
vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin (TTP399), a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary d
Key facts
- Headquarters
- North Carolina, United States
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (VTVT)
- Website
- vtvtherapeutics.com
- Company page
Recent activity at vTv Therapeutics Inc.
- : SEC 8-K (5.03): On October 1, 2026, vTv Therapeutics Inc. approved the adoption of its Third Amended and Restated By-Laws. This amendment includes new procedures for the nomination of directors, requiring stockholders to provide evidence of compliance with Rule 14a-19 of the Securities Exchange Act at least five business days prior to a meeting. Additionally, it revises the voting standards for stockholder meetings, enhancing the governance framework of the company. This change is significant as it may influence future elections and decision-making processes within the company.
- : SEC 8-K (8.01): On May 13, 2026, vTv Therapeutics Inc. filed a prospectus supplement to increase the number of Class A common stock shares offered under its at-the-market sales program (ATM Program) to the maximum allowable amount. The filing includes a legal opinion from Dechert LLP concerning the legality of the shares being issued through the ATM Program, which is attached as Exhibit 5.1. This move is strategic for the company to raise additional capital through the expanded share offering, reflecting an active financial strategy as part of their ongoing operations.
- : SEC 8-K (8.01): On May 13, 2026, vTv Therapeutics Inc. filed a prospectus supplement with the SEC to increase the number of shares of Class A common stock offered under its at-the-market sales program to the maximum amount allowed. This filing includes a legal opinion from Dechert LLP regarding the legality of the shares issued under the program. This expansion allows the company to take full advantage of market conditions for capital raising, which could support its operations and growth strategies moving forward.
- : SEC 8-K (7.01): On March 10, 2026, vTv Therapeutics, Inc. posted an updated slide presentation on its website, which is included as Exhibit 99.1 in the Form 8-K filing. This presentation is intended for use in various meetings with investors, analysts, and other interested parties. It allows the Company to update stakeholders on its developments and may be modified or replaced in future filings. The strategic implication of this update is to strengthen investor engagement and communication regarding the Company's activities and performance.
- : SEC 8-K (7.01): On March 10, 2026, vTv Therapeutics, Inc. issued a Regulation FD disclosure regarding an updated investor presentation, which is attached as Exhibit 99.1. This presentation will be utilized in various upcoming meetings with investors and analysts, highlighting the company's strategic initiatives and updates for stakeholders. The company indicates that the presentation may be amended or updated through further filings, ensuring that information remains current and relevant. This event is significant as it facilitates ongoing communication with investors, reflecting the company's commitment to transparency.
- : SEC 8-K (7.01): On February 26, 2026, vTv Therapeutics, Inc. posted an updated slide presentation on its website, which is part of their ongoing Regulation FD Disclosure. This presentation is intended to be used in various meetings with investors, analysts, and other parties, indicating the company’s engagement strategy with stakeholders. The presentation can be amended or updated at any time, showcasing the company's commitment to transparency and open communication. The information in this filing is not deemed 'filed' for liability purposes, which protects the company under Section 18 of the Exchange Act.
- : SEC 8-K (7.01): On February 26, 2026, vTv Therapeutics, Inc. issued a Regulation FD disclosure by posting an updated slide presentation on its website. The presentation is intended for use in meetings with investors, analysts, and other stakeholders, highlighting the company's recent developments and future strategy. This presentation can be amended or updated at any time and will be communicated through subsequent filings, ensuring that stakeholders receive timely information. The nature of the information shared is designed to enhance transparency and facilitate discussions regarding the company's performance and strategic initiatives.
- : vTv Therapeutics Enters Second Amendment to License Agreement with Newsoara Biopharma (date Fundz recorded it)
- : SEC 8-K (1.01): On January 30, 2026, vTv Therapeutics LLC entered into the Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. This amendment expands Newsoara's rights to the Company’s PDE4 inhibitor, HPP737, to include all countries worldwide contingent upon an upfront fee payment of $20 million. In addition to the upfront fee, Newsoara is obligated to pay vTv LLC up to $50 million in development milestones and $65 million in sales-related milestones. The original License Agreement was established on May 31, 2018, and a previous amendment to expand the rights lapsed in June 2025, making this Second Amendment a significant legal development.
- : SEC 8-K (1.01): On January 30, 2026, vTv Therapeutics LLC entered into the Second Amendment to a License Agreement with Newsoara Biopharma Co., Ltd., expanding Newsoara's rights to vTv's PDE4 inhibitor, HPP737, for a global reach. The agreement involves an upfront payment of $20 million and potential additional payments up to $50 million for development milestones, along with $65 million for sales-related milestones and royalties based on sales volumes. This amendment follows a previous agreement which became null in June 2025, indicating a significant repositioning for vTv in the licensing of its pharmaceutical assets. The terms of this amendment could greatly influence vTv's revenue depending on the performance of HPP737 in the market.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
vTv Therapeutics Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Feb 2024 | Venture | $51.0M |
| Oct 2019 | Seed | $2.0M |
| Jul 2019 | Seed | $4.0M |
| Jan 2019 | Seed | $1.5M |
| Aug 2018 | Venture | Undisclosed |
Leadership
- Howard Weiner, Director
- Noel Spiegel, Director
- Paul Savas, Director
- John Fry, Director
- Hersh Kozlov, Director
- Jeffrey Kindler, Director
Verified email and direct lines for vTv Therapeutics Inc.’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
vTv Therapeutics Inc. files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
vTv Therapeutics Inc. in the news
- vTv Therapeutics to Participate in September Investor Conferences - Yahoo Finance (Sep 02, 2026)
- vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease - GlobeNewswire (Oct 07, 2026)
- vTv Therapeutics Announces Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes - UNC Health (Feb 23, 2021)
- vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance (Aug 19, 2026)
- vTv Therapeutics Announces Completion of Enrollment in - GlobeNewswire (Oct 05, 2026)
- vTv Therapeutics Inc. (5VT0.F) Company Profile & Facts - Yahoo! Finance Canada (Feb 16, 2024)
- Cantex and Headlamp Health Forge Strategic Partnership to Accelerate Azeliragon Development via Agentic Precision Neuropsychiatry for Severe Depression and Fatigue in Patients with Multiple Sclerosis - PR Newswire (May 13, 2026)
- vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems - GlobeNewswire (Oct 27, 2026)
Companies similar to vTv Therapeutics Inc.
- OnKure Therapeutics, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Savara Inc · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- ISOThrive · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Arbutus · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Corvus Pharmaceuticals, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About vTv Therapeutics Inc.: questions and answers
What does vTv Therapeutics Inc. do?
vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin (TTP399), a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary d
Where is vTv Therapeutics Inc. headquartered?
vTv Therapeutics Inc. is headquartered in North Carolina, United States.
Has vTv Therapeutics Inc. raised funding?
Yes. Fundz has recorded 5 funding events for vTv Therapeutics Inc.. The most recent, $51.0M, was in Feb 2024.
What is the latest news on vTv Therapeutics Inc.?
On Feb 2, 2026, SEC 8-K (5.03): On October 1, 2026, vTv Therapeutics Inc. approved the adoption of its Third Amended and Restated By-Laws. This amendment includes new procedures for the nomination of directors, requiring stockholders to provide evidence of compliance with Rule 14a-19 of the Securities Exchange Act
Is vTv Therapeutics Inc. a public company?
Yes. vTv Therapeutics Inc. is publicly traded under the ticker VTVT.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy